Table 2.
Clinical parameters and association with AKT1 E17K mutation in previously untreated breast cancer patients (cohort A)
| Parameter | Total (N = 494) | Mutation | P-valuea (adjusted P-value) | |
|---|---|---|---|---|
| Wild type (n = 465) | AKT1 E17K (n = 29) | |||
| Age, years | 0.55 (1.00) | |||
| < 35 | 8 (1.6) | 8 (1.7) | 0 | |
| 35–65 | 255 (51.6) | 241 (51.8) | 14 (48.3) | |
| > 65 | 231 (46.8) | 216 (46.5) | 15 (51.7) | |
| Menopausal statusb | 0.34 (1.00) | |||
| Pre | 77 (15.6) | 74 (15.9) | 3 (10.3) | |
| Post | 381 (77.1) | 356 (76.6) | 25 (86.2) | |
| UICC stage | 0.04 (0.47) | |||
| I | 142 (28.7) | 129 (27.7) | 13 (44.8) | |
| II | 198 (40.1) | 187 (40.2) | 11 (37.9) | |
| III | 110 (22.3) | 105 (22.6) | 5 (17.2) | |
| IV | 44 (8.9) | 44 (9.5) | 0 | |
| Grade | 0.03 (0.38) | |||
| 1 | 72 (14.6) | 64 (13.8) | 8 (27.6) | |
| 2 | 315 (63.8) | 296 (63.7) | 19 (65.5) | |
| 3 | 107 (21.7) | 105 (22.6) | 2 (6.9) | |
| Lymph-node metastasis (N stage)c | 0.17 (1.00) | |||
| N0 | 238 (48.2) | 223 (48.0) | 15 (51.7) | |
| N1 | 138 (27.9) | 128 (27.5) | 10 (34.5) | |
| N2 | 78 (15.8) | 77 (16.6) | 1 (3.4) | |
| N3 | 39 (7.9) | 36 (7.7) | 3 (10.3) | |
| Distant metastasis (M stage) | 0.02 (0.25) | |||
| M0 | 450 (91.1) | 421 (90.5) | 29 (100) | |
| M1 | 44 (8.9) | 44 (9.5) | 0 | |
| Histologyd | 0.83 (1.00) | |||
| Ductal | 368 (74.5) | 346 (74.4) | 22 (75.9) | |
| Lobular | 89 (18.0) | 85 (18.3) | 4 (13.8) | |
| Mixed | 10 (2.0) | 9 (1.9) | 1 (3.4) | |
| Others | 23 (4.7) | 21 (4.5) | 2 (6.9) | |
| St. Gallen criteriae | 0.19 (1.00) | |||
| Luminal A | 210 (42.5) | 194 (41.7) | 16 (55.2) | |
| Luminal B1 | 53 (10.7) | 52 (11.2) | 1 (3.4) | |
| Luminal B2 | 231 (46.8) | 219 (47.1) | 12 (41.4) | |
| HER2 status | 0.03 (0.38) | |||
| IHC-Score (3+) | 37 (7.5) | 37 (8.0) | 0 | |
| IHC-Score (0 - 2+) | 457 (92.5) | 428 (92.0) | 29 (100) | |
| PR statusf | 0.91 (1.00) | |||
| Negative | 43 (8.7) | 41 (8.8) | 2 (6.9) | |
| Positive | 375 (75.9) | 356 (76.6) | 19 (65.5) | |
aLikelihood-ratio test for the hypothesis that the prevalence of AKT1 E17K mutation in breast cancer patients does not differ based on the respective clinical parameter. Displayed are only selected parameters
bMissing, n = 36. cMissing, n = 1. dMissing, n = 4. etumor grade was used instead of Ki-67 for subgrouping. fMissing, n = 76
Abbreviations: AKT1 v-akt murine thymoma viral oncogene, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, PR progesterone receptor, UICC Union for International Cancer Control